John Han

2.9k total citations · 1 hit paper
20 papers, 2.3k citations indexed

About

John Han is a scholar working on Rheumatology, Hematology and Genetics. According to data from OpenAlex, John Han has authored 20 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Rheumatology, 10 papers in Hematology and 5 papers in Genetics. Recurrent topics in John Han's work include Rheumatoid Arthritis Research and Therapies (11 papers), Autoimmune and Inflammatory Disorders Research (10 papers) and Chronic Lymphocytic Leukemia Research (5 papers). John Han is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (11 papers), Autoimmune and Inflammatory Disorders Research (10 papers) and Chronic Lymphocytic Leukemia Research (5 papers). John Han collaborates with scholars based in United States, Netherlands and Germany. John Han's co-authors include Désirée van der Heijde, Sudha Visvanathan, Jürgen Braun, Daniel Baker, Carrie Wagner, Mahboob U. Rahman, Chenglong Han, Piet Geusens, Mohan Bala and David E. Yocum and has published in prestigious journals such as Scientific Reports, Ophthalmology and Annals of the Rheumatic Diseases.

In The Last Decade

John Han

19 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double‐blind, placebo‐controlled, phase III trial

2008 444 citations Robert D. Inman, John C. Davis et al. Arthritis & Rheumatism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Han United States	17	1.9k	831	754	261	205	20	2.3k
William Shergy United States	19	1.2k 0.7×	481 0.6×	561 0.7×	300 1.1×	274 1.3×	24	1.9k
Y P M Goekoop-Ruiterman Netherlands	20	2.4k 1.3×	880 1.1×	399 0.5×	485 1.9×	225 1.1×	30	2.6k
J.H.L.M. van Groenendael Netherlands	16	1.9k 1.0×	744 0.9×	324 0.4×	406 1.6×	175 0.9×	22	2.1k
M V van Krugten Netherlands	14	1.7k 0.9×	640 0.8×	428 0.6×	336 1.3×	174 0.8×	19	2.1k
Kristina Forslind Sweden	28	2.5k 1.4×	688 0.8×	420 0.6×	320 1.2×	380 1.9×	81	3.0k
Alberto Spindler Argentina	18	1.2k 0.7×	351 0.4×	600 0.8×	205 0.8×	352 1.7×	41	1.7k
K. H. Han Netherlands	10	1.6k 0.8×	633 0.8×	243 0.3×	355 1.4×	147 0.7×	16	1.8k
Serena Bugatti Italy	28	1.3k 0.7×	301 0.4×	655 0.9×	244 0.9×	349 1.7×	89	2.1k
Masao Nawata Japan	24	1.2k 0.7×	344 0.4×	536 0.7×	316 1.2×	294 1.4×	47	1.8k
P.L. van Riel Netherlands	15	2.1k 1.2×	742 0.9×	349 0.5×	243 0.9×	130 0.6×	34	2.5k

Countries citing papers authored by John Han

Since Specialization

Citations

This map shows the geographic impact of John Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Han more than expected).

Fields of papers citing papers by John Han

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Han. The network helps show where John Han may publish in the future.

Co-authorship network of co-authors of John Han

This figure shows the co-authorship network connecting the top 25 collaborators of John Han. A scholar is included among the top collaborators of John Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Han. John Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Richarz, Ute, John Han, Ya‐Mei Bai, et al.. (2023). Efficacy and safety of paliperidone palmitate 6-monthly long-acting injectable in reduction of relapses in patients with schizophrenia: An Asian subgroup analysis of phase 3, randomized study. Medicine. 102(34). e34623–e34623.

Gevaert, Philippe, Claus Bachert, J. Mullol, et al.. (2019). D450 OMALIZUMAB EFFICACY AND SAFETY IN NASAL POLYPOSIS: RESULTS FROM TWO PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS. Annals of Allergy Asthma & Immunology. 123(5). S17–S17. 11 indexed citations

Rim, Tyler Hyungtaek, John Han, Jaewon Oh, et al.. (2016). Retinal vein occlusion and the risk of acute myocardial infarction development: a 12-year nationwide cohort study. Scientific Reports. 6(1). 22351–22351. 27 indexed citations

Rim, Tyler Hyungtaek, et al.. (2015). Retinal Vein Occlusion and the Risk of Stroke Development. Ophthalmology. 122(6). 1187–1194. 80 indexed citations

Yu, Shiying, et al.. (2014). Safety and Efficacy of Once-Daily Hydromorphone Extended-Release Versus Twice-Daily Oxycodone Hydrochloride Controlled-Release in Chinese Patients With Cancer Pain: A Phase 3, Randomized, Double-Blind, Multicenter Study. Journal of Pain. 15(8). 835–844. 19 indexed citations

Richarz, Ute, et al.. (2011). P4‐268: Efficacy and tolerability of two galantamine titration regimens in patients switched from donepezil. Alzheimer s & Dementia. 7(4S_Part_23). 1 indexed citations

Kremer, Joel M., Christopher T. Ritchlin, Alan M. Mendelsohn, et al.. (2010). Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty‐eight–week efficacy and safety results of a phase III randomized, double‐blind, placebo‐controlled study. Arthritis & Rheumatism. 62(4). 917–928. 105 indexed citations

Kay, Jonathan, Eric L. Matteson, Bhaskar DasGupta, et al.. (2008). Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double‐blind, placebo‐controlled, dose‐ranging study. Arthritis & Rheumatism. 58(4). 964–975. 246 indexed citations

Doyle, Mittie K., Mahboob U. Rahman, Chenglong Han, et al.. (2008). Treatment with Infliximab plus Methotrexate Improves Anemia in Patients with Rheumatoid Arthritis Independent of Improvement in Other Clinical Outcome Measures—A Pooled Analysis from Three Large, Multicenter, Double-Blind, Randomized Clinical Trials. Seminars in Arthritis and Rheumatism. 39(2). 123–131. 48 indexed citations

10.

Inman, Robert D., John C. Davis, Désirée van der Heijde, et al.. (2008). Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double‐blind, placebo‐controlled, phase III trial. Arthritis & Rheumatism. 58(11). 3402–3412. 444 indexed citations breakdown →

11.

Smolen, Josef S, Désirée van der Heijde, Daniel Aletaha, et al.. (2008). Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing. Annals of the Rheumatic Diseases. 68(10). 1535–1540. 53 indexed citations

12.

Visvanathan, Sudha, Désirée van der Heijde, Atul Deodhar, et al.. (2008). Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases. 68(2). 175–182. 103 indexed citations

13.

Visvanathan, Sudha, Carrie Wagner, Joseph C. Marini, et al.. (2007). Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Annals of the Rheumatic Diseases. 67(4). 511–517. 111 indexed citations

14.

Strusberg, Ingrid, Piet Geusens, David E. Yocum, et al.. (2007). Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 66(9). 1233–1238. 91 indexed citations

15.

Visvanathan, Sudha, Joseph C. Marini, Josef S Smolen, et al.. (2007). Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis.. PubMed. 34(7). 1465–74. 39 indexed citations

16.

Smolen, Josef S, Désirée van der Heijde, E. William St. Clair, et al.. (2006). Predictors of joint damage in patients with early rheumatoid arthritis treated with high‐dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial. Arthritis & Rheumatism. 54(3). 702–710. 342 indexed citations

17.

Smolen, Josef S, Chenglong Han, Désirée van der Heijde, et al.. (2006). Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis & Rheumatism. 54(3). 716–722. 90 indexed citations

18.

Heijde, Désirée van der, Chenglong Han, Gerd R Burmester, et al.. (2006). Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: Results from a randomized, placebo‐controlled trial. Arthritis Care & Research. 55(4). 569–574. 69 indexed citations

19.

Braun, Jürgen, Robert B M Landewé, Kay‐Geert Hermann, et al.. (2006). Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double‐blind, placebo‐controlled magnetic resonance imaging study. Arthritis & Rheumatism. 54(5). 1646–1652. 174 indexed citations

20.

Westhovens, René, David E. Yocum, John Han, et al.. (2006). The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: A large, randomized, placebo‐controlled trial. Arthritis & Rheumatism. 54(4). 1075–1086. 255 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact